Synartro AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Synartro AB - overview
Established
2011
Location
Stockholm, -, Sweden
Primary Industry
Healthcare
About
Based in Stockholm, Sweden, and founded in 2011 by Fredrik Lehmann, Synartro AB operates as a life science company providing preclinical lead program combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA). In 2021, Falvir AB acquired Synartro AB. Synartro AB developed a SYN321, which is an intraarticular injection designed to treat symptomatic knee osteoarthritis. The product ensures a slow release of diclofenac directly into the joint, SYN321 aims to reduce inflammation, prolong pain relief, and lubricate the joint, all while minimizing systemic exposure and side effects.
The company’s products diagnosis of mild knee osteoarthritis and provides second-line treatment intermittent, continuous oral NSAIDs (non-selective, COX-2 selective, naproxen).
Current Investors
Falvir
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Chiropractic, Orthopedic & Physical Therapy
Website
www.synartro.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Synartro AB - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 10,988 | 100,000 | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | 810.1% | (100.0%) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (21,127) | (9,211) | 74,701 | (47,082) | 139,983 | (93,932) | (2,490,692) | (4,980,602) | (7,996,266) | - | - | - |
| Operating Income (USD) | (21,127) | (9,211) | 74,701 | (47,082) | 139,983 | (99,920) | (2,496,680) | (4,986,590) | (8,013,362) | - | - | - |
| Operating Margin | - | (83.8%) | 74.7% | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | (83.8%) | 74.7% | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | 21,074 | 9,111 | 58,265 | (47,082) | (146,627) | (109,094) | (2,507,401) | (4,994,195) | (8,020,379) | - | - | - |
| % Net Margin | - | 82.9% | 58.3% | - | - | - | - | - | - | - | - | - |
Synartro AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.